Open Orphan Share Discussion Threads

[m5] 27/1/2021 16:38

That was bloody annoying but poor day on the markets.

[gregb] 27/1/2021 16:00

Adam, the Company has until July to issue full year results. Personally, I think CF will leave it as late as possible so he can give solid forward looking statements for the current year.

[adamb1978] 27/1/2021 15:42

Has anyone heard whether we should be expecting a Jan trading statement from the company? As I've mentioned before, I think it (i.e. 2020 figures) are required in order to attract new investors and take the share price to another level

[m5] 27/1/2021 15:23

Dire day for the markets and we are doing ok!!!

[bobsworth] 27/1/2021 14:50

Agree it's just a waiting game now before next news is announced.
Good to see us blue in a sea of red today.
Looking forward to the next presentation a week today and fingers crossed for another blue finish today.
GLA

[pogue] 27/1/2021 14:26

Pierre
Venn have foreign employees, CF sacked a load mind you. I am assuming he is going to open the SGS Belgian clinic with SGS existing staff and adding a few more locally with probably some existing Hvivo staff going over to kick things off, I assume they are there already as he said before Xmas they were setting up the new facility, not sure why he has still not confirmed the location mind you probably still agreeing the contract.
I suspect the new staff in London is to run the two existing clinics particularly the Royal Free as it has to be staffed by Hvivo as I dont think NHS staff will be working for us.
All going to plan, just sit and wait for me just now :0)

[m5] 27/1/2021 13:00

Pierre Oreilly27 Jan '21 - 11:38 - 11063 of 11064

Fair comments. We certainly know CF is risk adverse and that strategy would certainly be more in keeping with what we have seen and what know of the guy.

[pierre oreilly] 27/1/2021 11:42

The above re challenge studies abroad, or out of Europe at least.

[pierre oreilly] 27/1/2021 11:38

I hope c isn't ever going to hire abroad. Too many unknowns too much complexity too much risk. He's hands on. My hope and belief is he'll sign profit share jvs with any foreign pharmas/cros using all their facilities and staff and orph's expertise and IP. Just an hvivo pm out there for the duration. Quick, low risk, high profit. Repeat all over the planet, or at least where challenge studies are allowed.

[timberwolf3] 27/1/2021 11:21

CF was looking at the facility in St Louis, but there is no facility suitable in Lander.

[m5] 27/1/2021 11:18

Why would they put Lander, WY?

[cottoner] 27/1/2021 11:14

Edit - 1gw beat me to it :-)



Think the confusion is that some vacancies are listed as UK-London and a few as LND.

LND is being taken as being Lander , however if you look at the detail of the position , it clearly states London.

eg. Position for Clinical Support Specialist - Clinical Trials

LND
ID 2020-2495 Category Clinical Position Type Bank/Zero Hours
Overview
If you have exceptional customer service skills, a healthcare background and are interested in learning more about clinical trials, this is a fantastic opportunity to join our dynamic FluCamp team at our site in London.

[m5] 27/1/2021 11:12

Nice. I didn't look that closely at the adverts.

[1gw] 27/1/2021 11:11

I suspect the "Lander Wyoming" is a misinterpretation of the "LND" abbreviation used for some of the London job postings on the hVivo site listing.

[john henry] 27/1/2021 11:02

HVIVO Job vacancies.

[timberwolf3] 27/1/2021 11:01

CF dismissed speculation about Lander a couple of months ago in one of his presentations.

[m5] 27/1/2021 11:00

Really? Just Googled it!

[john henry] 27/1/2021 10:57

M5 Lander WY

[m5] 27/1/2021 10:53

Crusader527 Jan '21 - 10:30 - 11048 of 11049

No, but we know that news on a third facility is expected anytime. Location, no idea.

[john henry] 27/1/2021 10:50

Imho Invesco have stopped selling, added 2x50K tech target 27p then 32p

L2 strengthening

Brakes coming off.

[slartybartfaster] 27/1/2021 10:31

I made 3 purchase yesterday, all under £3k, all trough kill or fill. I couldn't get an online quote. The same for similar sized sells. No quite.

[crusader5] 27/1/2021 10:30

M5, any hint of where those new job positions were based?

[owenski] 27/1/2021 10:30

Meissa - (From 21st Jan.)

"The Phase 2 study is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and prophylactic efficacy of a single intranasal dose of MV-012-968 against symptomatic RSV infection in a virus challenge model. The company plans to enroll up to 70 adult participants, between ages 18 and 45 years, in the U.K. with the support of hVIVO, part of Open Orphan plc, the industry leading services provider of viral challenge studies. The ClinicalTrials.gov identifier is NCT04690335."

"Meissa and hVIVO share the same vision of using challenge studies to accelerate development of potential vaccines for infectious diseases, such as RSV,” said Cathal Friel, Executive Chairman and Cofounder of Open Orphan plc. “hVIVO is the only company globally offering the capability to conduct an RSV human challenge study, and we are pleased to have been selected to run this study by an organization with world-class expertise in vaccine development."